7441-43-2

Basic information

• Product Name: 4-ETHYLBENZYLAMINE
• Synonyms: 4-ETHYLBENZYLAMINE;4-Ethylbenzylamine,98%;4-EthylbenzylaMine, 98% 5GR;(4-ethylphenyl)MethanaMine;(4-Ethylphenyl);SALOR-INT L480800-1EA;RARECHEM AL BW 2167
• CAS NO: 7441-43-2
• Molecular Formula: C₉H₁₃N
• Molecular Weight: 135.21
• Product Categories: Anilines, Aromatic Amines and Nitro Compounds
• Mol File: 7441-43-2.mol

Chemical Properties

• Boiling Point: 208°C/700mmHg
• Flash Point: 90.8 °C
• Appearance: Clear colorless/Liquid
• Density: 0.94
• Vapor Pressure: 0.122mmHg at 25°C
• Refractive Index: 1.534
• PKA: 9.20±0.10(Predicted)
• CAS DataBase Reference: 4-ETHYLBENZYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-ETHYLBENZYLAMINE(7441-43-2)
• EPA Substance Registry System: 4-ETHYLBENZYLAMINE(7441-43-2)

Safety Data

• Hazard Codes: C
• HazardClass: AIR SENSITIVE, CORROSIVE
• Hazardous Substances Data: 7441-43-2(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H13N/c1-2-8-3-5-9(7-10)6-4-8/h3-6H,2,7,10H2,1H3

Upstream product

• 7664-41-7 ammonia 
• 4748-78-1 4-ethylbenzylaldehyde 
• 87171-25-3 1-[4-(aminomethyl)phenyl]ethan-1-one 
• 622-96-8 4-methylethylbenzene 
• 33241-76-8 1-ethyl-4-(nitromethyl)benzene 
• 1202873-20-8 1-ethyl-4-methylamino-2,5-cyclohexadiene-1-carboxylic acid 
• 540-69-2 ammonium formate 

Downstream Products

• 735331-14-3 N-(4-ethylbenzyl)-N'-(1-methyl-1H-indazol-4-yl)urea 
• 937247-96-6 (R)-tert-butyl 1-(4-ethylbenzylamino)-3-(1H-indol-3-yl)-1-thioxopropan-2-ylcarbamate 
• 1027277-31-1 C₃₈H₄₆N₆O₃ 
• 937248-77-6 (R)-tert-butyl 1-(4-(4-ethylbenzyl)-5-phenylethyl-4H-1,2,4-triazol-3-yl)-2-(1H-indol-3-yl)ethylcarbamate 
• 956489-60-4 (R)-tert-butyl 1-(4-ethylbenzylamino)-3-(1H-indol-3-yl)-1-oxopropan-2-ylcarbamate 
• 104851-76-5 3-chloro-propionic acid-(4-ethyl-benzylamide) 
• 4748-78-1 4-ethylbenzylaldehyde 
• 99858-48-7 N-(p-ethylbenzyl)acetamide 

Relevant articles and documents

Metal-Organic Framework-Confined Single-Site Base-Metal Catalyst for Chemoselective Hydrodeoxygenation of Carbonyls and Alcohols

Chemoselective deoxygenation of carbonyls and alcohols using hydrogen by heterogeneous base-metal catalysts is crucial for the sustainable production of fine chemicals and biofuels. We report an aluminum metal-organic framework (DUT-5) node support cobalt(II) hydride, which is a highly chemoselective and recyclable heterogeneous catalyst for deoxygenation of a range of aromatic and aliphatic ketones, aldehydes, and primary and secondary alcohols, including biomass-derived substrates under 1 bar H2. The single-site cobalt catalyst (DUT-5-CoH) was easily prepared by postsynthetic metalation of the secondary building units (SBUs) of DUT-5 with CoCl2 followed by the reaction of NaEt3BH. X-ray photoelectron spectroscopy and X-ray absorption near-edge spectroscopy (XANES) indicated the presence of CoII and AlIII centers in DUT-5-CoH and DUT-5-Co after catalysis. The coordination environment of the cobalt center of DUT-5-Co before and after catalysis was established by extended X-ray fine structure spectroscopy (EXAFS) and density functional theory. The kinetic and computational data suggest reversible carbonyl coordination to cobalt preceding the turnover-limiting step, which involves 1,2-insertion of the coordinated carbonyl into the cobalt-hydride bond. The unique coordination environment of the cobalt ion ligated by oxo-nodes within the porous framework and the rate independency on the pressure of H2 allow the deoxygenation reactions chemoselectively under ambient hydrogen pressure.

Enzymatic Primary Amination of Benzylic and Allylic C(sp3)-H Bonds

Aliphatic primary amines are prevalent in natural products, pharmaceuticals, and functional materials. While a plethora of processes are reported for their synthesis, methods that directly install a free amine group into C(sp3)-H bonds remain unprecedented. Here, we report a set of new-to-nature enzymes that catalyze the direct primary amination of C(sp3)-H bonds with excellent chemo-, regio-, and enantioselectivity, using a readily available hydroxylamine derivative as the nitrogen source. Directed evolution of genetically encoded cytochrome P411 enzymes (P450s whose Cys axial ligand to the heme iron has been replaced with Ser) generated variants that selectively functionalize benzylic and allylic C-H bonds, affording a broad scope of enantioenriched primary amines. This biocatalytic process is efficient and selective (up to 3930 TTN and 96percent ee), and can be performed on preparative scale.

Novel electronic salt system and method for reducing unsaturated hydrocarbon compound

The invention discloses an electronic salt system and a method for reducing unsaturated hydrocarbon compounds by using the electronic salt system, belongs to the field of organic synthesis, and solvesthe problems such as complicated operation, harsh conditions, easy generation of complex over-reduction products of methods for reducing the unsaturated hydrocarbon compounds in the prior art. An electron salt may be synthesized by an alkali metal reagent, an ether and an alcohol, the ether can be a crown ether or a cryptand; and the method adopts the electronic salt system, the unsaturated hydrocarbon compounds is reduced by the electronic salt system in an organic solvent. The method for reducing the unsaturated hydrocarbon compounds is used for reducing the unsaturated hydrocarbon compounds.

Regioselective arene functionalization: Simple substitution of carboxylate by alkyl groups

Arenes with various alkyl side-chains were synthesized in high yields and excellent regioselectivities. Starting from toluic and naphthoic acids, the carboxylate group was conveniently substituted by alkyl halides by Birch reduction and subsequent decarbonylation. The method is characterized by inexpensive starting materials and reagents, and methylation of arenes was realized. Besides simple alkyl substituents, the scope of arene functionalization was extended by benzyl, fluoro, amino, and ester groups. We were able to control the alkylation of 1-naphthoic acid during Birch reduction by the addition of tert-butanol. This allowed the regioselective synthesis of mono and bis-substituted naphthalenes from the same starting material.

Arylalkylamine vanadium (V) salts for the treatment and/or prevention of Diabetes mellitus

This invention provides compounds of formula (IIA) and pharmaceutical compositions thereof, where M, a, b, and R1-R5 are as defined herein, for treating human type 1 and type 2 diabetes, particularly insulin-resistant diabetes. Pharmaceutical compositions comprising the compounds of formula (IIA) are also disclosed.

New efficient substrates for semicarbazide-sensitive amine oxidase/VAP-1 enzyme: Analysis by SARs and computational docking

Structure activity relationships for semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1) were studied using a library of arylalkylamine substrates, with the aim of contributing to the discovery of more efficient SSAO substrates. Experimental data were contrasted with computational docking studies, thereby allowing us to examine the mechanism and substrate-binding affinity of SSAO and thus contribute to the discovery of more efficient SSAO substrates and provide a structural basis for their interactions. We also built a model of the mouse SSAO structure, which provides several structural rationales for interspecies differences in SSAO substrate selectivity and reveals new trends in SSAO substrate recognition. In this context, we identified novel efficient substrates for human SSAO that can be used as a lead for the discovery of antidiabetic agents.

O-glucosylated benzamide SGLT2 inhibitors and method

SGLT2 inhibiting compounds are provided having the formula wherein n is 0, 1 or 2; A is or heteroaryl which may contain 1 to 4 heteroatoms in the ring which may be selected from N, O, S, SO, and/or SO2, bearing substituents R3 and R4; and R1 to R4 are as defined herein. A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with one, two or more other antidiabetic agents and/or one, two or more hypolipidemic agents.